The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of verubulin (MPC-6827) for the treatment of subjects with recurrent glioblastoma naïve to treatment with bevacizumab.
L. J. Kim
Research Funding - Myrexis
M. C. Chamberlain
Research Funding - Myrexis
J. Zhu
Research Funding - Myrexis
J. J. Raizer
Research Funding - Myrexis
S. A. Grimm
Research Funding - Myrexis
S. Phuphanich
Research Funding - Myrexis
C. E. Fadul
Research Funding - Myrexis
S. Rosenfeld
Research Funding - Myrexis
A. H. Balch
Employment or Leadership Position - Myrexis
Stock Ownership - Myrexis
C. C. Pope
Employment or Leadership Position - Myrexis
Stock Ownership - Myrexis
M. Brulotte
Employment or Leadership Position - Myrexis
Stock Ownership - Myrexis
A. A. P. Beelen
Employment or Leadership Position - Myrexis
Stock Ownership - Myrexis
L. D. Recht
Research Funding - Myrexis